zurück

Pembrolizumab (new indication: melanoma, patients aged ≥ 12 years, adjuvant therapy, monotherapy)

 

Subject:

  • Active Sustance: Pembrolizumab
  • Name: Keytruda®
  • Therapeutic area: Melanoma
  • Pharmaceutical company: MSD Sharp & Dohme GmbH

 

Time table:

  • Start: 01.08.2022
  • Final decision by G-BA: 19.01.2023

 

Final decision:

  1. Adults with stage IIB or IIC melanoma after complete resection; adjuvant treatment: Indication for a non-quantifiable additional benefit
  2. Adolescents 12 years and older with stage IIB or IIC melanoma after complete resection; adjuvant treatment: No additional benefit proved